The medical test-making company Abbott has finalized its acquisition of Exact Sciences, the Madison-based maker of cancer screening and diagnostic tests, it said in a March 23 announcement. The deal, ...

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Exact Sciences has published a new case study on its collaboration with Amalgam Rx and ...

Joey Votto appeared on the Jim Day podcast earlier this week and told a fascinating story about the exact moment he knew his career as a baseball player was over. Day and Votto were talking about the ...

Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed ...

284 games of the 2025 NFL season are behind us. No. 285 will crown a world champion. Super Bowl 60 is a story of two turnarounds. The Seattle Seahawks jumped from good to great after ditching a likely ...

KANSAS CITY, Mo. (KCTV) - A change will impact some Black Friday shoppers this year. It’s one that many people out looking for deals won’t have considered before hitting the checkout line. Business ...

Being a life sciences CEO is not for the faint of heart. Drug discovery and patent approvals are costly and time-consuming, and even if an executive can steer a company to clinical trials, there’s a ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...